Home › Breast Cancer › NCT07291414
A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients
Patient Engagement in Using the Technology for Self-Tracking Medication Safety Events
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Participants are adult patients (aged 18 years or older) * Diagnosed with lung, colorectal, breast, or prostate cancer * Are currently receiving active cancer treatments * Are self-managing one or more prescribed cancer medications * Participants must have access to technology devices (smartphone, tablet, computer) to track their experiences or concerns about medication safety events, or their family members can help them access technology devices to track the events or concerns * Speaks and reads English or has a support person (family member or friend) who can assist Exclusion Criteria: * Can't access technology or do not use technology * Do not have access to the internet * Do not speak or read English * Not permitted to participate by their health care providers
About the study
This clinical trial evaluates the usefulness of a self-monitoring platform for tracking medication safety events and concerns in patients with lung, colorectal, breast, and prostate cancer. Patients receiving oral anticancer agents often encounter challenges in managing complex treatment regimens, potentially life-threatening toxicities, and drug-drug and drug-food interactions at home. To achieve the goal of medication safety, they need to become "vigilant partners" in medication and toxicity self-monitoring, including timely reporting of medication events to clinicians when their care transitions back home. In this study, patients use an online self-monitoring platform to track their experiences or concerns about taking their medications, including their experiences with symptoms. This platform may be a useful way for patients to track problems they have when taking their medications at home and may help them take better care of their health.
What is being tested
- Educational Intervention (other)
- Electronic Health Record Review (other)
- Follow-Up (procedure)
- Internet-Based Intervention (other)
- Interview (other)
- Survey Administration (other)
Sponsor: University of Michigan Rogel Cancer Center · Participants: 80 · Started: Jan 9, 2026
Contact the study team
- Yun Jiang · Phone: 734-763-3705
Official record on ClinicalTrials.gov — NCT07291414
Locations in the U.S.
| Michigan | University of Michigan Comprehensive Cancer Center, Ann Arbor |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.